title: International reporting scale of BCR-ABL1 fusion transcript in chronic myeloid leukemia: first report from India.
abstract: Achieving a major molecular response (MMR) is an important predictor of progression-free survival in chronic myeloid leukemia patients treated with imatinib. This requires accurate measurement of BCR-ABL1 transcripts normalized to a control gene, as well as defining a level (BCR-ABL1/control gene ratio) that will correlate with sustained clinical response. To make these measurements comparable between laboratories, an international scale (IS) is necessary. A BCR-ABL1/control gene ratio of 0.10% represents MMR in the IS. In collaboration with an international reference laboratory in Adelaide, S.A., Australia, we have established and validated a lab-specific conversion factor for expressing BCR-ABL1 transcript levels in the IS. In this report, we explain the process and steps involved in obtaining a valid lab-specific conversion factor for expressing BCR-ABL1 transcript levels in the IS.
authors.affiliation: Department of Haematology, Christian Medical College, Vellore, India. bpoonkuzhali@cmcvellore.ac.in
authors.forename: Poonkuzhali
authors.initials: P
authors.lastname: Balasubramanian
authors.forename: Ezhilarasi
authors.initials: E
authors.lastname: Chendamarai
authors.forename: Preetha
authors.initials: P
authors.lastname: Markose
authors.forename: Linda
authors.initials: L
authors.lastname: Fletcher
authors.forename: Susan
authors.initials: S
authors.lastname: Branford
authors.forename: Biju
authors.initials: B
authors.lastname: George
authors.forename: Vikram
authors.initials: V
authors.lastname: Mathews
authors.forename: Mammen
authors.initials: M
authors.lastname: Chandy
authors.forename: Alok
authors.initials: A
authors.lastname: Srivastava
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D019963:Clinical Chemistry Tests / Q000592:standards; D016044:Fusion Proteins, bcr-abl / Q000235:genetics / Q000378:metabolism* / Q000592:standards; D006801:Humans; D000068877:Imatinib Mesylate; D007194:India; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012015:Reference Standards
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl